ライフサイエンスコーパス: single-chain antibody

1 nst human p53, have been used to construct a single-chain antibody.

2 otherapy for HIV-1 using novel CARs based on single-chain antibodies.

3 -binding regions of the microcystin-specific single-chain antibody, 3A8, with constant regions from t

4 ha-syn::GFP was reduced by immunization with single chain antibodies against alpha-syn.

5 These results indicate that such chimeric single-chain antibodies against IGF1R have future potent

6 es Edmonston-NSe vaccine strain displaying a single-chain antibody against EGFRvIII at the COOH termi

7 pendent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a

8 We have previously shown that a chimeric single-chain antibody against IGF1R (scFv-Fc) and a muri

9 using three carbohydrate-binding proteins, a single chain antibody, an antigen binding fragment, and

10 on solutions containing a target protein (a single chain antibody, an antigen binding fragment, or a

11 Using a panel of single-chain antibodies and a single-chain T-cell recept

12 MegAnneal libraries based on three different single-chain antibodies and identified variants with enh

13 tely 100 million secreted and membrane-bound single-chain antibodies and identify antibodies that can

14 hile chimeric antigen receptors (CARs) using single-chain antibodies as binding domains are growing i

15 ould be useful in improving the stability of single-chain antibodies, as Ala/Met mutations at these c

16 een the antigen and a panel of small, 25 kDa single-chain antibodies at concentrations down to 1 nM.

17 This stable single chain antibody based heterodimer has simplified t

18 BNAbs varying in binding sites and generated single-chain-antibody-based CARs.

19 ge, complex domains (either a 252-amino-acid single-chain antibody binding domain [scFv] or a 96-amin

20 also be achieved using a retroviral receptor-single-chain antibody bridge protein, the TVA-MR1 fusion

21 here the development of a novel, bispecific single-chain antibody (bscAb) referred to as bscEphA2xCD

22 roperties are comparable to those for stable single-chain antibodies, but are markedly improved over

23 orted earlier the delivery of antiangiogenic single chain antibodies by using oncolytic vaccinia viru

24 self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 epsilon

25 ed a membrane-tethered anti-Igkappa-reactive single chain antibody chimeric gene and expressed it as

26 A humanized single-chain antibody component in which the variable do

27 mbinant proteins, and describe a new type of single chain antibody containing the entire heavy chain

28 ced Binding Site (LIBS-MBs) or a nonspecific single-chain antibody (control MBs).

29 of the FSTE with a growth factor ligand or a single-chain antibody, delivered a reporter gene selecti

30 Recognition of GD2 was provided by a single-chain antibody derived from the GD2-specific mono

31 ach requires development of a high-affinity, single chain antibody directed specifically against the

32 ticles of iron oxide (MPIOs) conjugated to a single-chain antibody directed against a ligand-induced

33 A single-chain antibody directed against IGF1R (IGF1R scFv

34 ately 5 nM) and specific localization to the single-chain antibody expressed in the endoplasmic retic

35 f chimeric antigen receptors (CARs) based on single-chain antibodies for gene immunotherapy of cancer

36 The 4M5.3 anti-fluorescein single chain antibody fragment (scFv) contains 14 mutati

37 mor targeting of a novel internalizing human single chain antibody fragment (scFv) labeled with ((9)(

38 lular expression of an inhibitory anti-ATF-1 single chain antibody fragment (ScFv).

39 llular expression of an inhibitory anti-ATF1 single chain antibody fragment (scFv4).

40 Here we show that a single chain antibody fragment (syn-10H scFv) isolated f

41 A single-chain antibody fragment (anti-1F12 scFv) was isol

42 alian cell line that expresses a recombinant single-chain antibody fragment (scFv) derived from an NS

43 nes with an adenovirus (AV1Y28) expressing a single-chain antibody fragment (scFv) directed against R

44 f a hypothesis-driven mathematical model for single-chain antibody fragment (scFv) folding in Sacchar

45 h the corresponding conventional ER-targeted single-chain antibody fragment (scFv) intrabodies demons

46 cluster of differentiation 3 (CD3)-specific single-chain antibody fragment (scFv), effectively redir

47 A prostate tumor-targeting single-chain antibody fragment (scFv), UA20, along with

48 body to its minimal functional unit (i.e., a single-chain antibody fragment [scFv]) is an effective s

49 of the AV1Y28 adenovirus, which expresses a single-chain antibody fragment directed against p21 Ras

50 sults demonstrate that the topically applied single-chain antibody fragment ESBA105 penetrated into t

51 By using a single-chain antibody fragment isolated from a bacteriop

52 ral vector was used to deliver a recombinant single-chain antibody fragment rabbit intrabody (pAd-2S0

53 ding and antigen-binding activity of a human single-chain antibody fragment were simultaneously impro

54 topic expression of an inhibitory anti-ATF-1 single-chain antibody fragment, ScFv, significantly inte

55 Here we show that single chain antibody fragments (scFv's) isolated from n

56 We were able to isolate single chain antibody fragments (scFvs) from a phage dis

57 ant antivenom composed of a few neutralizing single chain antibody fragments (scFvs) that bind to two

58 is intermediate in size between peptides and single chain antibody fragments, both of which are super

59 Here we develop single-chain antibody fragments (nanobodies) against tub

60 We have produced single-chain antibody fragments (scFv) in Saccharomyces

61 Single-chain antibody fragments (scFvs) are first isolat

62 arting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage

63 Here we show that human single-chain antibody fragments (three domain, V(H)/K fo

64 ariables by live-cell microscopic imaging of single-chain antibody fragments against carcinoembryonic

65 We further demonstrated that single-chain antibody fragments against tumor-specific a

66 assemblies for a monoclonal antibody and its single-chain antibody fragments derivatives.

67 It has previously been reported that several single-chain antibody fragments of human origin (scFv) n

68 ity/specificity trade-offs, we have selected single-chain antibody fragments specific for the negativ

69 Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity

70 ells expressing tumor-associated antigens by single-chain antibodies fused to a receptor-binding-defi

71 Furthermore, an ErbB2 single-chain antibody fused with protamine delivered siR

72 pes through the use of a retroviral receptor-single-chain antibody fusion protein.

73 odimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with m

74 ally inactive murine caspase-3, by screening single-chain antibody (Fv) phage display libraries.

75 f substantial levels of human monoclonal and single chain antibodies (>3 mg and >150 mg, respectively

76 unctional characterization of monoclonal and single-chain antibodies has become just as important as

77 The DO-1 single-chain antibody has been used to construct single-

78 es based on larger complex proteins, such as single chain antibodies, have stimulated interest in the

79 nscription are decorated specifically by the single-chain antibody HF1 and by the nuclear protein PAR

80 as evidenced by changes in the binding of a single-chain antibody highly specific for site B.

81 assessed using monoclonal antibody NV23 and single-chain antibody HJT-R3-A9 to identify both virus-l

82 inding kinetics of a recombinant mAb and its single-chain antibody homolog, single-chain variable fra

83 al growth factor]) or Hu-tagged anti-VEGFR-2 single-chain antibody (Hu-P4G7) and incubating on ice fo

84 ion X-ray structures of three high-affinity, single-chain antibodies in the 14B7 family; 14B7 and two

85 Intrabodies are engineered single-chain antibodies in which the variable domain of

86 Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in

87 This single-chain antibody is the first anti-P. falciparum ef

88 re identified by phage display from a biased single chain antibody library generated from the spleens

89 Yeast panning with a nonimmune human single-chain antibody library identified 34 unique lead

90 We have constructed a membrane-anchored single-chain antibody [m-scFv(HA)] which recognizes a li

91 o different recombinant reporter proteins, a single-chain antibody (M18 scFv) that contains two disul

92 Single-chain antibody mutants have been evolved in vitro

93 e second minireview describes application of single chain antibodies (nanobodies) for monitoring and

94 Single-chain antibodies neutralize activity and bind non

95 ignated ITEM4-rGel) and a humanized, dimeric single-chain antibody of ITEM-4 fused to rGel (designate

96 rating the Fc domain and either an anti-CD40 single-chain antibody or CD40L form stable complexes wit

97 We expressed a single chain antibody (p3S5) to KDR with or without the

98 A single-chain antibody phage display library was construc

99 To this end, we developed a single chain antibody (sc1E3) against hIL-1beta that exh

100 nd expressed in high yields, relative to the single chain antibody (SCA) derivative (2 3-fold), in Es

101 essed a chimeric Sindbis gp which included a single-chain antibody (SCA) directed to the human Her2/n

102 m spleen necrosis virus (SNV) that display a single-chain antibody (scA) on the viral surface.

103 omplementarity determining regions (CDRs) of single-chain antibody (scAb) fragments is demonstrated.

104 e displayed on the viral hemagglutinin (H) a single-chain antibody (scAb) specific for the tumor-asso

105 ed a new receptor by fusing a virus-binding, single-chain antibody (scAb) to intracellular adhesion m

106 t express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb),

107 GLAF-1, a previously undescribed engineered single-chain antibody (scAb).

108 iral vectors derived from SNV that displayed single-chain antibodies (scAs) directed against a carcin

109 We fused a single chain antibody (scFv Ter-119) that binds to mouse

110 ific antibodies by fusing the DNA encoding a single chain antibody (ScFv) after the C terminus (CH3-S

111 ing mesothelin-targeted TR3 variants using a single chain antibody (scFv) delivery format (SS-TR3), w

112 valently but specifically bound to a cognate single chain antibody (scFv).

113 We developed anti-Akt1 single-chain antibodies (scFv) by panning a mouse phage-

114 d rapid production and recovery of idiotypic single-chain antibodies (scFv) derived from each patient

115 First, we engineered a single-chain antibody (scFv) against the c-erbB2 oncopro

116 marker CD38 was constructed in the form of a single-chain antibody (scFv) and (2) display of that scF

117 ification, we constructed an anti-annexin IV single-chain antibody (scFv) and an scFv linked to Crry,

118 l binding interface consisting of a anti-Myc single-chain antibody (ScFv) and its peptide epitope.

119 of immunotoxins containing either the human single-chain antibody (scFv) C6.5 or the murine scFv e23

120 A uniform immunoreagent was prepared from a single-chain antibody (scFv) gene specific for digoxin.

121 o biopanning strategy in which a human phage single-chain antibody (scFv) library was injected into h

122 Using a phage display single-chain antibody (scFv) library, we developed a nov

123 Toward this end, we displayed a single-chain antibody (scFv) specific for the designated

124 ced by genetic fusion of a T84.66 (anti-CEA) single-chain antibody (scFv) to the human IgG1 CH3 domai

125 The corresponding single-chain antibody (scFv) was also prepared, offering

126 Conjugation to the corona of a single-chain antibody (scFv), which binds to the ligand-

127 We use a single-chain antibody (scFv, specific for activated GPII

128 ding epitopes of a panel of eight agonistic, single-chain antibody (scFv-Fc) constructs were determin

129 n order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Ral

130 as characterized by stable transfection of a single chain antibody (ScFv5R) against ErbB2 containing

131 stomize the in vivo behavior of an anti-METH single chain antibody (scFv7F9Cys).

132 m for the comparative functional analysis of single-chain antibodies (scFvs) expressed on the plasma

133 ns of rapidly selecting tailored linkers for single-chain antibodies (scFvs) from protein linker libr

134 i mosquitoes expressing m1C3, m4B7, or m2A10 single-chain antibodies (scFvs) have significantly lower

135 een isolated by screening a library of human single-chain antibodies (scFvs) using derivatives of thi

136 Anti-HPV16 E7 intracellular single-chain antibodies (scFvs) were constructed to down

137 venient 1E12 immunoreagent, we constructed a single chain antibody (sFv) using recombinant protein te

138 In particular, single-chain antibodies (sFv) have been reported to fold

139 superfamily, was fused to a gene encoding a single-chain antibody (sFv) against the human transferri

140 In this report, a non-immune human single-chain antibody (sFv) phage display library was us

141 these synthetic receptors was derived from a single-chain antibody (sFv) with specificity for Ad5 kno

142 r, coexpression of an intracellular anti-Rev single-chain antibody (SFv), which has been shown to int

143 roach based upon intracellular expression of single-chain antibodies (sFvs) to achieve modulation of

144 A recombinant PfCHT1/PgCHT2-neutralizing single-chain antibody significantly reduced P. falciparu

145 tilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, d

146 d gas-filled MBs were conjugated to either a single-chain antibody specific for activated glycoprotei

147 A single-chain antibody specific for human C5 is a safe an

148 A humanized, recombinant, single-chain antibody specific for human C5, h5G1.1-scFv

149 show that custom superantigens generated by single chain antibody technology permit the study of tol

150 n, we generated a CSPG4-specific fully human single-chain antibody termed scFv-FcC21 and characterize

151 orm for the selection of very high affinity, single-chain antibodies that have tremendous potential a

152 achment of sporozoites to salivary glands; a single-chain antibody that agglutinates sporozoites; or

153 n leukosis viruses (ALV-A), fused to the MR1 single-chain antibody that binds specifically to EGFRvII

154 We have developed a single-chain antibody that is selective for G-quadruplex

155 is-regulatory elements to express an encoded single-chain antibody that prevents the P3A2 protein fro

156 mpetitive selection techniques to generate a single-chain antibody that shows >1000-fold discriminati

157 s approach we have developed a CCR5-specific single-chain antibody that was expressed intracellularly

158 e enhanced by inclusion of sequences such as single-chain antibodies to target the antigen to DCs.

159 cDNA transfection was used to target a single-chain antibody to a specified site such as an org

160 exclusion; this was fused to a CD3-specific single-chain antibody to generate bscEphA2xCD3.

161 F) was expressed, consisting of a His tag, a single-chain antibody to the myeloid antigen CD33, and t

162 A single chain antibody variable domain (scFv) phage displ

163 We generated a single chain antibody variable fragment (scFv) that bind

164 and experimental validation of two different single-chain antibody variable fragment libraries that e

165 Single-chain antibody variable fragments (scFv) derived

166 using two different binding scaffold types (single-chain antibody variable fragments and fibronectin

167 we have generated immune-challenged chicken single-chain antibody variable-region fragment (scFv) li

168 rapeutic applications.The therapeutic use of single-chain antibodies (VHHs) is limited by their short

169 A CD7-specific single-chain antibody was conjugated to oligo-9-arginine

170 al vector (33E67) containing a CD33-specific single-chain antibody was generated in an attempt to tar

171 An EphA2-specific single-chain antibody was selected for recognition of an

172 Three different single-chain antibodies were displayed at the extracellu

173 A 27 kDa single chain antibody, which binds to both ligands, serv